Advanced glycation as a basis for understanding retinal aging and noninvasive risk prediction

Annals of the New York Academy of Sciences

Volumn 1126, Issue , 2008, Pages 59-65

  Pawlak, Anna M ^a   Glenn, Josephine V ^a   Beattie, James R ^a   McGarvey, John J ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Advanced glycation; Aging; Raman spectroscopy; Retina

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; POLYUNSATURATED FATTY ACID;

AGING; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; GLYCATION; HUMAN; PATHOGENESIS; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAMAN SPECTROMETRY; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION;

EID: 42549150071     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1433.066     Document Type: Conference Paper

References (65)

1. 1 Beckman, K.B. & B.N. Ames. 1998. The free radical theory of aging matures. Physiol. Rev. 78: 547–581.
2. 2 Szweda, P.A. et al. 2003. Aging, lipofuscin formation, and free radical‐mediated inhibition of cellular proteolytic systems. Ageing Res. Rev. 2: 383–405.
3. 3 Yin, D. & K. Chen. 2005. The essential mechanisms of aging: irreparable damage accumulation of biochemical side‐reactions. Exp. Gerontol. 40: 455–465.
4. 4 Grune, T. et al. 2004. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during oxidative stress, aging, and disease. Int. J. Biochem. Cell. Biol. 36: 2519–2530.
5. 5 Louie, J.L., R.J. Kapphahn & D.A. Ferrington. 2002. Proteasome function and protein oxidation in the aged retina. Exp. Eye. Res. 75: 271–284.
6. 6 Boulton, M. et al. 2004. The photoreactivity of ocular lipofuscin. Photochem. Photobiol. Sci. 3: 759–764.
7. 7 Terman, A., B. Gustafsson & U.T. Brunk. 2007. Autophagy, organelles and ageing. J. Pathol. 211: 134–143.
8. 8 Strauss, O. 2005. The retinal pigment epithelium in visual function. Physiol. Rev. 85: 845–881.
9. 9 Starita, C. et al. 1996. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp. Eye. Res. 62: 565–572.
10. 10 Guymer, R., P. Luthert & A. Bird. 1999. Changes in Bruch's membrane and related structures with age. Prog. Retin. Eye. Res. 18: 59–90.
11. 11 Binder, S. et al. 2007. Transplantation of the RPE in AMD. Prog. Retin. Eye. Res. 26: 516–554.
12. 12 Ambati, J. et al. 2003. Age‐related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48: 257–293.
13. 13 Boulton, M. & P. Dayhaw‐Barker. 2001. The role of the retinal pigment epithelium: topographical variation and ageing changes. Eye 15: 384–389.
14. 14 Boulton, M., M. Rozanowska & T. Wess. 2004. Ageing of the retinal pigment epithelium: implications for transplantation. Graefes. Arch. Clin. Exp. Ophthalmol. 242: 76–84.
15. 15 Bird, A.C. et al. 1995. An international classification and grading system for age‐related maculopathy and age‐related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 39: 367–374.
16. 16 Feeney‐Burns, L. & G.E. Eldred. 1983. The fate of the phagosome: conversion to ‘age pigment’ and impact in human retinal pigment epithelium. Trans. Ophthalmol. Soc. U. K. 103 (Pt 4): 416–421.
17. 17 Klein, R. et al. 2002. Ten‐year incidence and progression of age‐related maculopathy: The Beaver Dam eye study. Ophthalmology 109: 1767–1779.
18. 18 Beatty, S. et al. 2000. The role of oxidative stress in the pathogenesis of age‐related macular degeneration. Surv. Ophthalmol. 45: 115–134.
19. 19 Algvere, P.V. & S. Seregard. 2002. Age‐related maculopathy: pathogenetic features and new treatment modalities. Acta. Ophthalmol. Scand. 80: 136–143.
20. 20 Hjelmeland, L.M. et al. 1999. Senescence of the retinal pigment epithelium. Mol. Vis. 5: 33.
21. 21 Hageman, G.S. et al. 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age‐related macular degeneration. Proc. Natl. Acad. Sci. USA 102: 7227–7232.
22. 22 Zarbin, M.A. 2004. Current concepts in the pathogenesis of age‐related macular degeneration. Arch. Ophthalmol. 122: 598–614.
23. 23 Kijlstra, A., E. La Heij & F. Hendrikse. 2005. Immunological factors in the pathogenesis and treatment of age‐related macular degeneration. Ocul. Immunol. Inflamm. 13: 3–11.
24. 24 Penfold, P.L. et al. 2001. Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye. Res. 20: 385–414.
25. 25 Roberts, J.E. 2001. Ocular phototoxicity. J. Photochem. Photobiol. B 64: 136–143.
26. 26 Boulton, M., M. Rozanowska & B. Rozanowski. 2001. Retinal photodamage. J. Photochem. Photobiol. B 64: 144–161.
27. 27 Baynes, J.W. 2001. The role of AGEs in aging: causation or correlation. Exp. Gerontol. 36: 1527–1537.
28. 28 Monnier, V.M. et al. 1992. Maillard reaction‐mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41 (Suppl 2): 36–41.
29. 29 Thorpe, S.R. & J.W. Baynes. 2003. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275–281.
30. 30 Thornalley, P.J., A. Langborg & H.S. Minhas. 1999. Formation of glyoxal, methylglyoxal and 3‐deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 (Pt 1): 109–116.
31. 31 Bazan, N.G. 1982. Metabolism of phospholipids in the retina. Vision Res. 22: 1539–1548.
32. 32 Januszewski, A.S. et al. 2003. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans. 31: 1413–1416.
33. 33 Schutt, F. et al. 2003. Proteins modified by malondialdehyde, 4‐hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 44: 3663–3668.
34. 34 Howes, K.A. et al. 2004. Receptor for advanced glycation end products and age‐related macular degeneration. Invest. Ophthalmol. Vis. Sci. 45: 3713–3720.
35. 35 Handa, J.T. et al. 1999. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest. Ophthalmol. Vis. Sci. 40: 775–779.
36. 36 Yamada, Y. et al. 2006. The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp. Eye. Res. 82: 840–848.
37. 37 Ishibashi, T. et al. 1998. Advanced glycation end products in age‐related macular degeneration. Arch. Ophthalmol. 116: 1629–1632.
38. 38 Swamy‐Mruthinti, S. et al. 2002. Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization. Curr. Eye. Res. 25: 139–145.
39. 39 Rumble, J.R. et al. 1997. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J. Clin. Invest. 99: 1016–1027.
40. 40 Handa, J.T. et al. 1998. The advanced glycation endproduct pentosidine induces the expression of PDGF‐B in human retinal pigment epithelial cells. Exp. Eye. Res. 66: 411–419.
41. 41 Kobayashi, S. et al. 2007. Overproduction of N(epsilon)‐(carboxymethyl)lysine‐induced neovascularization in cultured choroidal explant of aged rat. Biol. Pharm. Bull. 30: 133–138.
42. 42 Zhou, J. et al. 2005. Mechanisms for the induction of HNE‐ MDA‐ and AGE‐adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp. Eye. Res. 80: 567–580.
43. 43 Stitt, A.W. 2001. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 85: 746–753.
44. 44 Tian, J. et al. 2005. Advanced glycation endproduct‐induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response. Proc. Natl. Acad. Sci. USA 102: 11846–11851.
45. 45 Cheng, Y. & M.H. Gao. 2005. The effect of glycation of CD59 on complement‐mediated cytolysis. Cell. Mol. Immunol. 2: 313–317.
46. 46 Munch, G., J. Gasic‐Milenkovic & T. Arendt. 2003. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. J. Neural. Transm. Suppl. 63–71.
47. 47 Bierhaus, A. et al. 2005. Advanced glycation end product receptor‐mediated cellular dysfunction. Ann. N.Y. Acad. Sci. 1043: 676–680.
48. 48 Schmidt, A.M. et al. 2000. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498: 99–111.
49. 49 Wautier, J.L. & A.M. Schmidt. 2004. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95: 233–238.
50. 50 Justilien, V. et al. 2007. SOD2 knockdown mouse model of early AMD. Invest. Ophthalmol. Vis. Sci. 48: 4407–4420.
51. 51 Ma, W. et al. 2007. RAGE ligand upregulation of VEGF secretion in ARPE‐19 cells. Invest. Ophthalmol. Vis. Sci. 48: 1355–1361.
52. 52 McFarlane, S. et al. 2005. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br. J. Ophthalmol. 89: 107–112.
53. 53 Glenn, J.V. et al. 2007. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. Faseb J. 21: 3542–3552.
54. 54 Takeuchi, M. et al. 2001. Immunological detection of a novel advanced glycation end‐product. Mol. Med. 7: 783–791.
55. 55 Odetti, P. et al. 1992. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41: 153–159.
56. 56 Portero‐Otin, M., R.H. Nagaraj & V.M. Monnier. 1995. Chromatographic evidence for pyrraline formation during protein glycation in vitro and in vivo. Biochim. Biophys. Acta 1247: 74–80.
57. 57 Verzijl, N. et al. 2000. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275: 39027–39031.
58. 58 Sebekova, K., L. Podracka, P. Blazicek, et al. 2001. Plasma levels of advanced glycation end products in children with renal disease. Pediatr. Nephrol. 16: 1105–1112.
59. 59 Mulder, D.J. et al. 2008. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis. 197: 217–223.
60. 60 Notingher, I., J. Selvakumaran & L.L. Hench. 2004. New detection system for toxic agents based on continuous spectroscopic monitoring of living cells. Biosens. Bioelectron. 20: 780–789.
61. 61 Buschman, H.P. et al. 2001. Raman microspectroscopy of human coronary atherosclerosis: biochemical assessment of cellular and extracellular morphologic structures in situ. Cardiovasc. Pathol. 10: 69–82.
62. 62 Erckens, R.J. et al. 2002. Raman spectroscopy: noninvasive determination of silicone oil in the eye: potential applications for intraocular determination of biomaterials. Retina 22: 796–799.
63. 63 Beattie, J.R. et al. 2007. Raman microscopy of porcine inner retinal layers from the area centralis. Mol. Vis. 13: 1106–1113.
64. 64 Bernstein, P.S. et al. 2004. Resonance Raman measurement of macular carotenoids in the living human eye. Arch. Biochem. Biophys. 430: 163–169.
65. 65 Okubo, A. et al. 1999. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. Invest. Ophthalmol. Vis. Sci. 40: 443–449.